Endometrial Adenosquamous Carcinoma — Trials

Endometrial Adenosquamous Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00977574	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	active not recruiting	Phase 2	349	National Cancer Institute (NCI)NIH	1	Sep 9, 2026	clinicaltrials
NCT01935934	Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	completed	Phase 2	102	National Cancer Institute (NCI)NIH	2	Oct 1, 2025